Cancer Commons founder Marty Tenenbaum, PhD, will speak at the NYC Oncology Investor Conference on October 30. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.
Read the synopsis of Marty’s presentation, “Can AI Cure Cancer?”: No one knows the optimal way to treat any cancer with currently available therapies. When clinical advances are made, it can take years for you and your doctor to find out about them. Getting access to breakthrough therapies, in a clinical trial or through expanded access, is problematic. Developing a new drug from scratch can take a decade or more and cost upwards of a billion dollars. AI can help. I will outline a plan, with the potential to save many thousands of lives, and a strategy for funding it through philanthropy and impact investing.
The NYC Oncology Investor Conference brings together “leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies, and cancer foundations for a discussion of trends, opportunities, and risks in oncology investing, corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science.”
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak May 11 at the Stanford AI Salon, a regular event hosted by the Stanford University Artificial Intelligence Laboratory. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments in a talk titled “How can AI cure cancer?”
According to the event website, “AI Salon is a roughly bi-weekly event on Fridays where the AI Lab gathers to discuss high-level topics in AI and machine learning. The goal is to encourage ourselves to think beyond our individual day-to-day research, and better see how our work fits into the long-term trajectory of scientific progress, and into society as a whole. Each Salon has a different topic for discussion, which is led by two speakers: typically one expert guest, and one AI Lab member. We hold the event in the spirit of Enlightenment-era salons, with no electronics or whiteboard allowed: only free-ranging discussion among attendees, starting with a 10-minute opening statement from the two speakers.”
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Bio-IT World Conference & Expo in Boston, which runs May 15 to 18. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments.
AI can beat go and drive cars, but can it beat cancer? Every year, many thousands of cancer patients die unnecessarily because their doctors do not know the optimal way to treat them with currently available therapies. Physicians and patients alike struggle with information overload and conflicting expert opinions in making treatment decisions. Moreover, effective treatments increasingly involve intelligently designed, individually tailored, sequences and combinations, and there are far more plausible multi-drug regimens than can be efficiently tested in clinical trials. AI can help by connecting physicians and patients to the right information at the right time, and by planning and coordinating the thousands of formal and informal treatment experiments that take place daily in oncology, to optimize individual outcomes and maximize collective knowledge. We will describe a developing global collaboration to realize this bold vision, involving leading oncologists, cancer and data scientists, and AI experts from both academia and industry, and discuss opportunities for all to participate.
The Bridging Clinical Research & Clinical Health Care Collaborative is “the only forum where clinical research and health care professionals come together to envision a collaborative solution that strengthens the connection between clinical research and health care.” Learn more about the event at https://www.bridgingclinical.com/agenda/.
A little more than four years ago, longtime friends Tom and Carman Duvall, and Kiers and Steve Rowley reminisced at dinner about their lives in the 1980s, long before their schedules had grown complicated and filled with endless trips driving children to various activities.
Tom, a child of 1980s rock and roll, wondered aloud whether Def Leppard might perform for them on his next birthday. Conversation meandered during the evening, and when the check arrived, Tom and Steve advised Kiers and Carman that a date had been set for a rock concert on the Duvall property in Independence, Missouri, and that it would be a fundraising event to support patients suffering with cancer. Kiers, who’d struggled with lung cancer for the past five years, and Carman announced “We’re in.” So began an all-day-long summer music festival and tradition resembling Woodstock, that the four friends named Tomstock. Continue reading…
Last week, Cancer Commons founder Marty Tenenbaum spoke at the Precision Medicine World Conference (PMWC) in Durham, NC. He presented a proposal to significantly accelerate patient access to promising investigational drugs, using a new pathway to approval by the U.S. Food and Drug Administration (FDA).
The proposed Conditional Approval pathway aims to help cancer patients who may have exhausted existing options access new, promising treatments.
“It’s an idea whose time has come, and the conference provided strong validation, including some personal communications from several prominent FDA officials (past and present) who were in attendance,” Marty says. “We are currently in discussions with the FDA, and hope to be able to pilot Conditional Approval in brain cancer where the prognosis is dire.”
Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Precision Medicine World Conference (PMWC) in Durham, NC, which runs May 24–25. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the organization’s ongoing efforts to address challenges to knowledge-sharing in precision oncology.
Read the synopsis of Marty’s presentation, entitled “Is An Additional Path to FDA Approval Possible?”:
This talk will explore the question: When faced with certain death, it is acceptable to accept less than 100% proven safety and efficacy?Patients with glioblastoma and certain other cancers with dire prognoses do not have the time to wait for new treatments to be fully approved by the FDA. Is it time to add “conditional approval” as an additional pathway to approval for these patients? In this session, a plan will be proposed by which the FDA could conditionally approve a treatment that has been proven safe in a clinical trial(s) with at least 25 patients, and has demonstrated biologic activity. Therefore, this treatment could not be denied by insurance as being “experimental”. However, the requires patients using these drugs to participate in a registry through which their physicians submit details on the treatments, side effects and outcomes. The FDA’s periodic review of the registry data would lead to a range of outcomes from full approval to the conditional approval being revoked.
Marty’s talk takes place on May 24 at 2:45 pm. For more information, visit the PMWC website.
Oncologist and Cancer Commons Medical Director Kevin Knopf, MD, will speak next month at TiEcon 2017, a technology conference in Santa Clara, CA. He’ll join three other experts to discuss the future of personalized medicine. From the program:
A new era of personalized medicine has made its way into the world of healthcare. We will discuss novel approaches for designing disease treatment and prevention that integrates with an individual’s genetic profile, environment and lifestyle.The future is here — let’s hear from industry luminaries on how digital health entrepreneurs and the healthcare industry as a whole are preparing for massive disruption.
Kevin’s presentation will take place on May 5 at 3:00 pm. For more information, visit the TiEcon website.
Update 3-1-17: A video of this event has now been released. Watch it below.
This year’s Precision Medicine World Conference in Mountain View, California, was well-attended by many members of Cancer Commons, who shared in the scientific discoveries that will lead the way to more personalized, accurate, and effective cancer care. Precision medicine is a rapidly evolving field with many breakthroughs in science, technology, and diagnosis that is transforming the way cancer care is practiced at the bedside.
A special session was co-chaired by Cancer Commons board member Larry Marton and Lincoln Nadauld, director of the personalized oncology program at Intermountain Healthcare in Utah. The session also featured Cancer Commons medical director Kevin Knopf, Mountain View oncologist Edmund Tai, and Tim Collins, who is corporate vice president of operations and research at Scripps Health in San Diego. Continue reading…